LTR Pharma is a Clinical Stage Biopharmaceutical Company
Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.
SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects
LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years
worldwide expected cases by 2025
minute effectiveness
projected global market value 2024
ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.
LTR Pharma (ASX: LTP) has confirmed the first patient-specific ROXUS® prescriptions received through Mavrox, Shed’s men’s health telehealth platform, have now been fulfilled in the United States. ROXUS is LTR Pharma’s intranasal medication for erectile dysfunction support. The milestone marks the start of prescription activity under LTR Pharma’s agreements with
At the Asia-Pacific Prostate Cancer Conference (APCC) in Melbourne, Nurse Practitioner and Sexologist Melissa Hadley Barrett presented outcomes from 147 men who used SPONTAN nasal spray with a 93% response among men seeking greater convenience and spontaneity. The retrospective study included 147 treatment-experienced men prescribed SPONTAN® in routine Australian clinical practice, making it
LTR Pharma has received the final Clinical Study Report for its SPONTAN® Phase II pharmacokinetic study. The report completes the pharmacokinetic dataset agreed with the FDA for LTR Pharma’s planned U.S. 505(b)(2) submission. LTR’s SPONTAN® is a fast-acting intranasal spray for the treatment of erectile dysfunction, enabling an onset of
SPONTAN may be prescribed to eligible patients under the TGA’s Special Access Scheme. For more information, please register your details via our online form.